Cargando…

Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist

Introduction: Orchidectomy is currently the preferred method to induce bone loss in preclinical male osteoporosis model. Gonadotropin-releasing hormone (GnRH) agonists used in prostate cancer treatment can induce testosterone deficiency but its effects on bone in preclinical male osteoporosis model...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamad, Nur-Vaizura, Che Zulkepli, Muhammad Afiq Amani, May Theseira, Krystine, Zulkifli, Norain, Shahrom, Nur Quraisha, Ridzuan, Nurul Amni Mohamad, Jamil, Nor Aini, Soelaiman, Ima-Nirwana, Chin, Kok-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835701/
https://www.ncbi.nlm.nih.gov/pubmed/29511366
http://dx.doi.org/10.7150/ijms.22732
_version_ 1783303850518642688
author Mohamad, Nur-Vaizura
Che Zulkepli, Muhammad Afiq Amani
May Theseira, Krystine
Zulkifli, Norain
Shahrom, Nur Quraisha
Ridzuan, Nurul Amni Mohamad
Jamil, Nor Aini
Soelaiman, Ima-Nirwana
Chin, Kok-Yong
author_facet Mohamad, Nur-Vaizura
Che Zulkepli, Muhammad Afiq Amani
May Theseira, Krystine
Zulkifli, Norain
Shahrom, Nur Quraisha
Ridzuan, Nurul Amni Mohamad
Jamil, Nor Aini
Soelaiman, Ima-Nirwana
Chin, Kok-Yong
author_sort Mohamad, Nur-Vaizura
collection PubMed
description Introduction: Orchidectomy is currently the preferred method to induce bone loss in preclinical male osteoporosis model. Gonadotropin-releasing hormone (GnRH) agonists used in prostate cancer treatment can induce testosterone deficiency but its effects on bone in preclinical male osteoporosis model are less studied. Objective: This study aimed to evaluate the skeletal effect of buserelin (a GnRH agonist) in male rats and compare it with orchidectomy. Methods: Forty-six three-month-old male Sprague-Dawley rats were divided into three experimental arms. The baseline arm (n=6) was sacrificed at the onset of the study. In the buserelin arm, the rats received a daily subcutaneous injection of either normal saline (n=8), buserelin acetate at 25 µg/kg (n=8) or 75 µg/kg (n=8). In the orchidectomy arm, the rats were either sham-operated (n=8) or orchidectomized (n=8). All groups underwent in-vivo X-ray micro-computed tomography scanning at the left proximal tibia every month. Blood was collected at the beginning and the end of the study for testosterone level evaluation. The rats were euthanized after the three-month treatment. The femurs were harvested for biomechanical strength and bone calcium determination. Results: The results showed that buserelin at both doses caused a significant decline in testosterone level and deterioration in bone microstructure (p<0.05), but did not affect bone calcium content (p>0.05). Buserelin at 25 µg/kg decreased displacement and strain of the femur significantly (p<0.05). Similar changes were observed in the orchidectomized group compared to the sham-operated group but without any significant changes in biomechanical strength (p>0.05). Conclusion: Buserelin can induce testosterone deficiency and the associated deterioration of bone microarchitecture similar to orchidectomy in three months. However, it may require a longer time to show significant effects on bone strength and mineral content.
format Online
Article
Text
id pubmed-5835701
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-58357012018-03-06 Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist Mohamad, Nur-Vaizura Che Zulkepli, Muhammad Afiq Amani May Theseira, Krystine Zulkifli, Norain Shahrom, Nur Quraisha Ridzuan, Nurul Amni Mohamad Jamil, Nor Aini Soelaiman, Ima-Nirwana Chin, Kok-Yong Int J Med Sci Research Paper Introduction: Orchidectomy is currently the preferred method to induce bone loss in preclinical male osteoporosis model. Gonadotropin-releasing hormone (GnRH) agonists used in prostate cancer treatment can induce testosterone deficiency but its effects on bone in preclinical male osteoporosis model are less studied. Objective: This study aimed to evaluate the skeletal effect of buserelin (a GnRH agonist) in male rats and compare it with orchidectomy. Methods: Forty-six three-month-old male Sprague-Dawley rats were divided into three experimental arms. The baseline arm (n=6) was sacrificed at the onset of the study. In the buserelin arm, the rats received a daily subcutaneous injection of either normal saline (n=8), buserelin acetate at 25 µg/kg (n=8) or 75 µg/kg (n=8). In the orchidectomy arm, the rats were either sham-operated (n=8) or orchidectomized (n=8). All groups underwent in-vivo X-ray micro-computed tomography scanning at the left proximal tibia every month. Blood was collected at the beginning and the end of the study for testosterone level evaluation. The rats were euthanized after the three-month treatment. The femurs were harvested for biomechanical strength and bone calcium determination. Results: The results showed that buserelin at both doses caused a significant decline in testosterone level and deterioration in bone microstructure (p<0.05), but did not affect bone calcium content (p>0.05). Buserelin at 25 µg/kg decreased displacement and strain of the femur significantly (p<0.05). Similar changes were observed in the orchidectomized group compared to the sham-operated group but without any significant changes in biomechanical strength (p>0.05). Conclusion: Buserelin can induce testosterone deficiency and the associated deterioration of bone microarchitecture similar to orchidectomy in three months. However, it may require a longer time to show significant effects on bone strength and mineral content. Ivyspring International Publisher 2018-01-19 /pmc/articles/PMC5835701/ /pubmed/29511366 http://dx.doi.org/10.7150/ijms.22732 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Mohamad, Nur-Vaizura
Che Zulkepli, Muhammad Afiq Amani
May Theseira, Krystine
Zulkifli, Norain
Shahrom, Nur Quraisha
Ridzuan, Nurul Amni Mohamad
Jamil, Nor Aini
Soelaiman, Ima-Nirwana
Chin, Kok-Yong
Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist
title Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist
title_full Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist
title_fullStr Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist
title_full_unstemmed Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist
title_short Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist
title_sort establishing an animal model of secondary osteoporosis by using a gonadotropin-releasing hormone agonist
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835701/
https://www.ncbi.nlm.nih.gov/pubmed/29511366
http://dx.doi.org/10.7150/ijms.22732
work_keys_str_mv AT mohamadnurvaizura establishingananimalmodelofsecondaryosteoporosisbyusingagonadotropinreleasinghormoneagonist
AT chezulkeplimuhammadafiqamani establishingananimalmodelofsecondaryosteoporosisbyusingagonadotropinreleasinghormoneagonist
AT maytheseirakrystine establishingananimalmodelofsecondaryosteoporosisbyusingagonadotropinreleasinghormoneagonist
AT zulkiflinorain establishingananimalmodelofsecondaryosteoporosisbyusingagonadotropinreleasinghormoneagonist
AT shahromnurquraisha establishingananimalmodelofsecondaryosteoporosisbyusingagonadotropinreleasinghormoneagonist
AT ridzuannurulamnimohamad establishingananimalmodelofsecondaryosteoporosisbyusingagonadotropinreleasinghormoneagonist
AT jamilnoraini establishingananimalmodelofsecondaryosteoporosisbyusingagonadotropinreleasinghormoneagonist
AT soelaimanimanirwana establishingananimalmodelofsecondaryosteoporosisbyusingagonadotropinreleasinghormoneagonist
AT chinkokyong establishingananimalmodelofsecondaryosteoporosisbyusingagonadotropinreleasinghormoneagonist